The factors that cause prolonged human influenza virus respiratory tract infection and determine its clinical impact and the development of drug-resistant viruses are unclear.
Introduction
Human influenza viruses cause frequent morbidity and mortality, particularly in highrisk populations [1] . Antiviral drugs are important for treatment of infection and control of transmission during seasonal and pandemic influenza [2] . The recent and unexplained widespread emergence of circulating human influenza viruses with reduced sensitivity to adamantanes and neuraminidase (NA) inhibitors (NAIs) is therefore of major concern [2-5] . The potential modes by which NAI-resistant influenza viruses emerge merit further analysis. Particularly among children and immunocompromised hosts, prolonged viral excretion is associated with a higher incidence of drug resistance during antiviral therapy [6] [7] [8] [9] [10] [11] [12] [13] . The frequency with which such prolonged influenza viral excretion occurs, the clinical consequences of this condition, the development of antiviral resistance, and its correlation with impaired cell-mediated immunity are unclear, however [1, 14] . During a 3-year period, these questions were addressed through careful analysis of findings in 8 patients who presented with prolonged influenza virus respiratory tract infection.
Methods
Patients and specimens. The study included patients with prolonged influenza virus respiratory tract infection (defined below) observed at Leiden University Medical Center from March 2005 through April 2008. Respiratory specimens were obtained during episodes of symptomatic respiratory tract disease. Routine follow-up sampling was not performed during asymptomatic episodes that occurred in patients with established prolonged influenza virus infection, except for patient 1 and on single occasions for patients 3-6 to document complete viral clearance. Influenza virus type A or B RNA was detected in respiratory specimens by reverse-transcriptase polymerase chain reaction (PCR) [15] . Medical records were reviewed for underlying immunodeficiency and clinical characteristics during presentation, follow-up, and outcome, including upper or lower respiratory tract infection symptoms, intubation, antiviral therapy, viral clearance, leukocyte counts, hematopoietic stem cell transplantation (HSCT), and survival.
Minimum cell count percentages for granulocytes, monocytes, and lymphocytes determined within 1 week before or after initial detection of viral RNA (i.e., onset) were correlated with percentages determined within 2 weeks after final influenza virus RNA detection or within 1 week before fatal influenza pneumonia.
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Definitions. Prolonged influenza virus respiratory tract infection was defined as PCRpositive status combined with symptomatic respiratory tract disease for ≥2 weeks after primary laboratory confirmation of influenza virus infection. This definition is based on documented maximum durations of excretion and approximate median duration of symptoms among immunocompetent children (duration of excretion, <14 days; duration of symptoms, 7.1 days) [16, 17] and adults (duration of excretion, 5.5 days; duration of symptoms, 6 days) [18, 19] and mean durations of excretion among immunocompromised autologous HSCT recipients (6.7 days) and allogeneic HSCT recipients (11.1 days) [20] .
Influenza lower respiratory tract infection was diagnosed clinically (as dyspnea) and by PCR, and fatal influenza pneumonia was diagnosed by histology and PCR of pulmonary tissue specimens. Minimum reference cell counts for granulocytes (1800 cells/mm 3 ), monocytes (135 cells/mm 3 ), and lymphocytes (900 cells/mm 3 ) were used for adults, and pediatric values were age dependent. These thresholds were used to determine granulocytopenia, monocytopenia, and lymphocytopenia. Precursor virus was defined as influenza virus detected in a patient before antiviral therapy was started. Seasonal viruses were defined as community-acquired influenza viruses collected from patients with influenza-like illness or acute respiratory infection who had consulted a general practitioner involved in the sentinel surveillance system in The Netherlands. Baseline NAI susceptibility for seasonal viruses was defined as the IC 50 value (i.e., the mean concentration of NAI needed to inhibit the NA enzyme activity by 50%), after removal of outlier IC 50 values. NAI drug resistance was defined as a viral IC 50 value ≥8-fold higher than that of the corresponding sensitive precursor virus [21] and detection of specific NA gene mutations known to confer NAI drug resistance. In the absence of a precursor virus isolate, the IC 50 of a presumed drug-resistant isolate was compared with baseline NAI susceptibility to calculate the n-fold change in drug susceptibility.
Influenza virus characterization and drug susceptibility testing. Influenza viruseswere cultured in Madin-Darby canine kidney cells from specimens stored at -80°C.
Antigens were characterized by hemagglutination inhibition testing, as described elsewhere [22] . Phenotypic susceptibility (IC 50 ) for oseltamivir carboxylate (GS4071; Roche Diagnostics) and zanamivir (GG167; GlaxoSmithKline) was determined as described elsewhere [23] . Emergence of NAI-resistant viruses was confirmed by phenotypic and sequence analysis of precursor viruses. Influenza virus RNA was extracted from culture supernatant or clinical specimens using the QIAamp Viral RNA kit (Table 1) . These patients' underlying diseases included hematological malignancy (n = 7) and severe combined immunodeficiency (n = 1). The duration of symptoms observed by healthcare workers before the first detection of influenza virus was 2 days for patient 5 (coryza and fever), 2 days for patient 8 (dyspnea), 4 days for patients 2 and 3 (dyspnea and fever), 14 days for patient 6 (cough), and 20 days for patient 7 (cough). For patient 1, the duration of symptoms (cough) was 6 weeks before the first viral isolation, according to the history provided by a parent. Symptom duration could not reliably be determined for patient 4, who had chronic underlying pulmonary disease. Lymphocytopenia was more common at the onset of prolonged influenza virus infection (8 of 8 patients) than were granulocytopenia (2 of 8 patients) or monocytopenia (2 of 8 patients). Detection of antiviral-resistant viruses. Five of 8 patients were treated with oseltamivir ( Figure 1) . Two of the 5 (patients 4 and 8) were excluded from resistance analysis because of low viral levels and no viral growth or because of NAI-resistant precursor influenza virus. Among the 3 patients for whom resistance analysis was performed (patients 1-3), NAI-resistant viruses emerged in patients 1 and 2. In patient 1, an influenza A (H3N2) NA gene R292K escape mutant emerged during therapy, with a >7000-fold increase in resistance to oseltamivir and a >20-fold increase in resistance to zanamivir, compared with precursor virus (Table 1) . This virus reverted to an NA gene E119V mutant virus that had ~100-fold reduced susceptibility to oseltamivir compared with precursor virus but was sensitive to zanamivir (Table 1) , and 2 rapidly cleared the virus after lymphocyte reconstitution that followed successful HSCT (patient 5) or spontaneous lymphocyte reconstitution that followed "mild" lymphocytopenia (i.e., 55% of reference minimum cell count)
Influenza virus characterization.
at onset (patient 6).
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Discussion
The occurrence and clinical manifestations of prolonged influenza virus respiratory tract infection and the associated risk of developing antiviral resistance are poorly documented. This study included 8 immunocompromised patients who had symptomatic prolonged viral excretion for ≥2 weeks, with development of influenza lower respiratory tract infection in 6 patients (10 episodes) and frequent detection of drug resistance after therapy.
The occurrence of prolonged influenza virus infection among 8 patients during a 3-year period in a hospital setting appeared to be more common than would have been expected from the few cases documented in the literature [8] [9] [10] [11] [12] . All 8 patients in the current study who had prolonged influenza virus infection were immunocompromised with lymphocytopenia, but a few presented with either granulocytopenia (2 of 8 patients) or monocytopenia (2 of 8 patients). This suggests that unimpaired cellmediated immunity is important for the timely elimination of influenza viruses, a result that agrees with earlier observations [14] . In this study, complete viral clearance was associated with lymphocyte reconstitution (P = .04) (Figure 2 ) and was never observed within the first 2 weeks after oseltamivir therapy (Figure 1 ). This provides new evidence that complete influenza virus clearance depends on lymphocyte reconstitution, irrespective of receipt of oseltamivir therapy. Variable outcomes among patients who never received antiviral therapy indicate that the level and duration of lymphocytopenia could determine later outcome during prolonged influenza virus infection.
NAI-resistant influenza viruses emerged in 2 (67%) of 3 patients eligible for resistance analysis. This rate is much higher than incidences of oseltamivir resistance reported for immunocompetent adults or adolescents (0.33%-2%) and pediatric patients (4%-18%)
during clinical trials [6, 7, 13] . Emergence of NAI-resistant influenza viruses was confirmed in patients 1 and 2. In patient 1, an influenza A (H3N2) virus with NA gene R292K substitution, which conferred high-level oselta mivir resistance (>7000-fold increase, compared with precursor virus) and zanamivir resistance (>20-fold increase, compared with precursor virus) (Table 1) , emerged from wild-type NAI-sensitive precursor virus during oseltamivir therapy during the summer months. There was no molecular variability that would suggest the presence of a mixed population. This was followed by the rapid emergence of influenza virus with NA gene E119V framework mutation, which conferred reduced oseltamivir susceptibility (~100-fold decrease),
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In patient 2, a mixed population of NA gene R292K (10%) and NA gene E119V (90%) mutants with HA gene A138S substitution at the receptor binding site and reduced NAI susceptibility emerged during oseltamivir therapy and reverted back to wild-type NAIsensitive virus after antiviral treatment was discontinued. The emergence of R292K substitution in viruses from patients 1 and 2, which confers high-level oseltamivir resistance and reduced zanamivir susceptibility, is of concern because these mutants hamper therapy with NAIs. Apparently, with selective pressure and lack of immunological containment, NAI-resistant minor variant viruses can emerge that retain their replicative ability and evade antiviral therapy. The cessation of oseltamivir therapy allowed reversion to sensitive wild-type influenza virus A (H3N2) in patient 2, a result consistent with prior findings [8, 9] and in contrast to the result observed for patient 1, in whom the E119V mutation remained fixed after cessation of oseltamivir therapy and until viral clearance.
None of the patients received adamantane therapy; it was considered unreliable because of the rapid development of resistance [2, 3] . The M2 protein S31N substitution in viruses from patients 2 and 3 was not unexpected, because most 2006 national sentinel influenza A (H3N2) viruses also displayed this amino acid substitution (data not shown).
The detected M2 protein A30S substitution in patient 1 was apparently acquired by spontaneous mutation and therefore unrelated to exposure, as has been proposed earlier for the S31N mutation [5] . A30S mutation has been observed in vivo in avian influenza virus A(H7N2) field isolates [26] . M2 protein mutations at position 30, conferring amantadine resistance are typically A30V or A30T in humans [27] ; we are not aware of documented A30S mutation in human influenza viruses.
Lymphocytopenia at the time of infection has been documented as an important risk factor for developing influenza virus pneumonia [20] . In this study, the occurrence of influenza lower respiratory tract infection in 6 (75%) of 8 patients and the subsequent fatal outcome in 2 (33%) of 6 patients was similar to the rates of infection and death (80% and 33%, respectively) reported among severely immunocompromised patients further exploration of therapeutic approaches that aim to improve specific immune recovery during prolonged influenza infection. These strategies are important for the improvement of individual outcomes and for helping to prevent the emergence and continuous excretion of drug-resistant viruses.
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